CN101951936A - 用于防止和治疗急性肾损伤的方法 - Google Patents

用于防止和治疗急性肾损伤的方法 Download PDF

Info

Publication number
CN101951936A
CN101951936A CN2009801062159A CN200980106215A CN101951936A CN 101951936 A CN101951936 A CN 101951936A CN 2009801062159 A CN2009801062159 A CN 2009801062159A CN 200980106215 A CN200980106215 A CN 200980106215A CN 101951936 A CN101951936 A CN 101951936A
Authority
CN
China
Prior art keywords
group
kidney
phe
peptide
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801062159A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·塞托
迪亚娜·费尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Priority to CN201711096798.4A priority Critical patent/CN107802821A/zh
Priority to CN201610848820.5A priority patent/CN106975070A/zh
Publication of CN101951936A publication Critical patent/CN101951936A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2009801062159A 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法 Pending CN101951936A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201711096798.4A CN107802821A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201610848820.5A CN106975070A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3158508P 2008-02-26 2008-02-26
US61/031,585 2008-02-26
PCT/US2009/035132 WO2009108695A2 (en) 2008-02-26 2009-02-25 Methods for prevention and treatment of acute renal injury

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201410319216.4A Division CN104056248A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201610848820.5A Division CN106975070A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201711096798.4A Division CN107802821A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法

Publications (1)

Publication Number Publication Date
CN101951936A true CN101951936A (zh) 2011-01-19

Family

ID=41013650

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2009801062159A Pending CN101951936A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201410319216.4A Pending CN104056248A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201610848820.5A Pending CN106975070A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201711096798.4A Pending CN107802821A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201410319216.4A Pending CN104056248A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201610848820.5A Pending CN106975070A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法
CN201711096798.4A Pending CN107802821A (zh) 2008-02-26 2009-02-25 用于防止和治疗急性肾损伤的方法

Country Status (7)

Country Link
US (9) US8143219B2 (https=)
EP (3) EP3741381B1 (https=)
JP (5) JP5677096B2 (https=)
CN (4) CN101951936A (https=)
DK (1) DK2262520T3 (https=)
HK (1) HK1202429A1 (https=)
WO (1) WO2009108695A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
CN109160936A (zh) * 2011-12-09 2019-01-08 康德生物医疗技术公司 芳香族阳离子肽及其用途
CN109946139A (zh) * 2019-02-28 2019-06-28 东南大学 一种石蜡切片免疫组化套染pas试剂盒及其染色方法和应用
CN111686239A (zh) * 2019-03-11 2020-09-22 中国科学院微生物研究所 抗真菌化合物的应用
CN119215059A (zh) * 2023-06-28 2024-12-31 兰州大学 右磷丝氨酸在用于制备预防和/或治疗肾损伤药物中的应用

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604286T3 (pl) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CN104788540B (zh) 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
US8585597B2 (en) * 2010-03-12 2013-11-19 Sonogenix, Inc. Renal injury inhibiting devices, systems, and methods employing low-frequency ultrasound or other cyclical pressure energies
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2012092238A1 (en) * 2010-12-31 2012-07-05 Zeus Scientific, Inc. Improved methods for determining cell viability using molecular nucleic acid-based techniques
EP3108975A1 (en) * 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
WO2012158518A1 (en) * 2011-05-13 2012-11-22 The Penn State Research Foundation Treatment of renal injury
CA2844792A1 (en) * 2011-08-10 2013-02-14 Digna Biotech, S.L. Use of cardiotrophin-1 for the treatment of kidney diseases
CN106913860A (zh) * 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
WO2013074966A1 (en) * 2011-11-17 2013-05-23 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase activating polypeptide (pacap) and pacap analogs for treating contrast -indused nephropathy
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
ES2755134T3 (es) * 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9895410B2 (en) 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
US10905818B2 (en) * 2014-03-31 2021-02-02 Zoll Medical Corporation Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US10696631B2 (en) * 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
CN107644976B (zh) * 2016-07-22 2020-09-29 清华大学 锂离子电池电极
CA3044270A1 (en) 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____
CN111542518B (zh) 2017-10-03 2023-10-10 由卫生与公众服务部部长代表的美利坚合众国 埃文斯蓝衍生物的化学缀合物及其作为放射治疗剂和成像剂的用途
CN111741751B (zh) 2018-02-22 2024-06-28 美国政府健康及人类服务部 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
WO2020018381A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
WO2020214518A1 (en) * 2019-04-18 2020-10-22 Arcuate Therapeutics, Inc. Methods of treating renal conditions using peptides that improve mitochondrial function
CN110250110A (zh) * 2019-07-11 2019-09-20 南京医科大学附属逸夫医院 一种顺铂所致急性肾损伤的小鼠模型的构建方法
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN113209294B (zh) * 2020-02-05 2023-06-13 复旦大学 Dor激动剂在制备对抗肾脏纤维化药物中的应用
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
KR102308991B1 (ko) 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
BR112022020283A2 (pt) * 2020-04-08 2022-12-06 Aptabio Therapeutics Inc Agente para tratamento de lesão renal aguda induzida por contraste
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
CN116390723B (zh) 2020-09-09 2024-12-31 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物
IL301305A (en) * 2020-09-11 2023-05-01 Renibus Therapeutics Inc Method for treating cancer with kidney protection
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
WO1994028012A1 (en) * 1993-05-28 1994-12-08 Warner-Lambert Company Hydroxamate inhibitors of endothelin converting enzyme
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
US7498297B2 (en) 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
AU2002256092C1 (en) 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP1599216B9 (en) 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
CN109160936A (zh) * 2011-12-09 2019-01-08 康德生物医疗技术公司 芳香族阳离子肽及其用途
US12065511B2 (en) 2011-12-09 2024-08-20 Stealth Biotherapeutics Inc. Aromatic-cationic peptides and uses of same
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
CN109946139A (zh) * 2019-02-28 2019-06-28 东南大学 一种石蜡切片免疫组化套染pas试剂盒及其染色方法和应用
CN111686239A (zh) * 2019-03-11 2020-09-22 中国科学院微生物研究所 抗真菌化合物的应用
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
CN119215059A (zh) * 2023-06-28 2024-12-31 兰州大学 右磷丝氨酸在用于制备预防和/或治疗肾损伤药物中的应用

Also Published As

Publication number Publication date
HK1246673A1 (en) 2018-09-14
US20180177840A1 (en) 2018-06-28
CN107802821A (zh) 2018-03-16
US20090221514A1 (en) 2009-09-03
JP2015063561A (ja) 2015-04-09
HK1202429A1 (en) 2015-10-02
JP2011513241A (ja) 2011-04-28
JP2017226697A (ja) 2017-12-28
CN106975070A (zh) 2017-07-25
JP2019059785A (ja) 2019-04-18
EP3243521A1 (en) 2017-11-15
US20170112893A1 (en) 2017-04-27
EP2262520A2 (en) 2010-12-22
US11628198B2 (en) 2023-04-18
WO2009108695A2 (en) 2009-09-03
US20150353602A1 (en) 2015-12-10
US8940696B2 (en) 2015-01-27
EP2262520A4 (en) 2012-02-29
JP2016175924A (ja) 2016-10-06
US8143219B2 (en) 2012-03-27
US20230398172A1 (en) 2023-12-14
EP3741381B1 (en) 2024-04-24
WO2009108695A3 (en) 2009-12-30
JP5677096B2 (ja) 2015-02-25
US20130017150A1 (en) 2013-01-17
CN104056248A (zh) 2014-09-24
EP3741381A1 (en) 2020-11-25
EP3243521B1 (en) 2020-05-27
US20190388492A1 (en) 2019-12-26
EP2262520B1 (en) 2017-05-03
US8592373B2 (en) 2013-11-26
DK2262520T3 (en) 2017-08-07
US20140107033A1 (en) 2014-04-17
US20210023161A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US20230398172A1 (en) Methods for prevention and treatment of acute renal injury
CN104225574B (zh) 用于防止线粒体通透性改变的方法
JP6319738B2 (ja) 虚血／再灌流障害に続くノーリフローの予防又は処置方法
CN106913860A (zh) 芳族阳离子肽和使用它们的方法
CN104994912A (zh) 肽治疗剂及其使用方法
HK1235712A1 (en) Methods for prevention and treatment of acute renal injury
HK1246673B (en) A peptide for use for prevention and treatment of acute renal injury
Henderson et al. MP060 EXISTENCE OF THE AUTOREACTIVE T CELLS FOUND IN GOODPASTURE’S DISEASE IS ACCOUNTABLE BY PROPERTIES OF ENDOSOMAL PROCESSING

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110119